Sign up Australia
Proactive Investors - Run By Investors For Investors

Antisense Therapeutics Limited in ASX trading halt

Antisense Therapeutics Limited in ASX trading halt

Antisense Therapeutics Limited (ASX:ANP) is preparing to outline details in relation to the ATL1103 program for multiple sclerosis.

Antisense has been granted a trading halt to prepare, with its shares placed in pre-open.

The halt will remain in place until the opening of trade on Wednesday 9th March 2016, or earlier if an announcement is made to the market.

 

Proactive Investors is a global leader reporting financial news, media, research and hosts events for listed emerging growth companies and investors across four continents.

View full ANP profile

Antisense Therapeutics Timeline

Related Articles

eye-766166_1280_583251a48f148.jpg
November 21 2016
The flagship product, CardioCel, is a bio-engineered tissue scaffold used in the heart valve repair market.
Drugs
February 07 2017
The hybrid pharma services and drug development group has hit some key milestones over this year as trial results are eyed.
cancer cells
January 25 2017
The US-based, London-listed healthcare group topped expectations with its latest results and analysts are tipping it for more success this year

© Proactive Investors 2017

Proactive Investors Australia PTY LTD ACN:132787654 ABN:19132787654.